Market Overview

Expert: Biogen Is Closing In On The 'Holy Grail' For Biotech Stocks

Share:
Related BIIB
Biogen's Best-In-Class R&D Earn Makes It A Buy
5 Biggest Price Target Changes For Tuesday

In this week's episode, Estimize is joined by Joe McCann, a former biotech analyst at CR Intrinsic and the CEO of Slingshot Insights.

In the episode, Joe discusses Biogen Inc (NASDAQ: BIIB)'s new drug, which could be the holy grail for biotech stocks. Leigh and Joe also chat about a hedge fund that seeks to make drug prices cheaper, and wrap things up with a complete earnings overview for the biotech sector.

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: Biogen biogen idecAnalyst Color Biotech Long Ideas Trading Ideas General

 

Related Articles (BIIB)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...